RIPK2 inhibitors have already shown promise in the treatment of experimental autoimmune encephalomyelitis (EAE), the murine model for MS.12 Whether this effect was because of inhibition of the ER stress response during EAE or the inhibition of PGN-induced RIPK2 activation remains to be determined. The gene discussed is RIPK2; the disease is myeloid sarcoma.